Our Grants

CIRM provides funding across five key areas: Infrastructure, Education, Discovery Research, Translational Research, and Clinical Research. By supporting projects at every stage of development, from initial discovery to clinical trials, CIRM drives progress in regenerative medicine and accelerates innovative therapies to patients.

See our complete portfolio of awards below.

All CIRM Grants

Search Filters »

Institution Researcher name Grant Type Grant Title Award Value
University of California, San Diego Dr. David A. Cheresh Basic Biology V CD61-driven stemness program in epithelial cancer $1,161,000
University of California, Berkeley Dr. Andrew Dillin Basic Biology V A Requirement for Protein Homeostasis in the Mediation of Stem Cell Health $1,034,100
Stanford University Xinnan Wang Basic Biology V Misregulated Mitophagy in Parkinsonian Neurodegeneration $1,174,943
University of Southern California Mark Salman Humayun Disease Team Therapy Development III Phase 1 Safety Assessment of CPCB-RPE1, hESC-derived RPE Cell Coated Parylene Membrane Implants, in Patients with Advanced Dry Age Related Macular Degeneration $16,339,827
University of California, Davis Peter Belafsky Disease Team Therapy Development III Tissue Engineered Recellularized Laryngotracheal Implants $3,181,162
University of California, Los Angeles Dr. Dennis J Slamon Disease Team Therapy Development III A Phase I dose escalation and expansion clinical trial of the novel first-in-class Polo-like Kinase 4 (PLK4) inhibitor, CFI-400945 in patients with advanced solid tumors $5,683,693
Stanford University Professor Irving L Weissman MD Disease Team Therapy Development III Clinical Investigation of a Humanized Anti-CD47 Antibody in Targeting Cancer Stem Cells in Hematologic Malignancies and Solid Tumors $6,505,568
University of California, Los Angeles Dr. Donald B. Kohn Disease Team Therapy Development III Clinical Trial of Stem Cell Gene Therapy for Sickle Cell Disease $10,351,535
University of California, San Diego Thomas J Kipps Disease Team Therapy Development III Therapeutic Eradication of Cancer Stem Cells with UC-961 (Cirmtuzumab) $4,179,598
Sangamo BioSciences, Inc. Dr. Fyodor D Urnov Strategic Partnership II A Treatment For Beta-thalassemia via High-Efficiency Targeted Genome Editing of Hematopoietic Stem Cells $2,760,540
Human BioMolecular Research Institute Dr. John R Cashman Ph.D. Patent Assistance Fund Awards Intellectual Property for Stem Cell-Related Inventions – HBRI $50,000
University of California, San Francisco Karin Immergluck PhD Patent Assistance Fund Awards Patent Assistance Fund Proposal – UCSF $87,257
University of California, Davis David McGee Patent Assistance Fund Awards CIRM Patent Prosecution Assistance Fund for Stem Cell Technologies – UCD $48,595
University of California, Santa Barbara Bernadette McCafferty Patent Assistance Fund Awards Intellectual Property in Regenerative Bioengineering from CIRM funded research in regenerative medicine at the University of California, Santa Barbara. $23,564
University of California, Irvine Ronnie Hanecak Patent Assistance Fund Awards CIRM Patent Assistance Fund Application – UCI $46,155
University of California, Los Angeles Adele Rennie Patent Assistance Fund Awards Patent Assistance Fund – UCLA $84,973
Stanford University Katharine Ku Patent Assistance Fund Awards Funding for Patent Applications for CIRM-funded Inventions out of Stanford University $3,525
University of California, San Diego Dr. Rubén D. Flores Patent Assistance Fund Awards Patent Assistance Fund Application – UCSD $38,162
University of California, San Diego Dr. Lawrence S. B. Goldstein Early Translational from Disease Team Conversion Stem Cell-Derived Astrocyte Precursor Transplants in Amyotrophic Lateral Sclerosis $4,139,754
University of California, Los Angeles Dr. Irvin SY Chen Early Translational from Disease Team Conversion Development of a humanized mouse model for testing anti-HIV HSPC gene therapy strategies in HIV-1 infected mice. $1,505,000
University of California, Los Angeles Dr. Stanley Nelson Early Translational from Disease Team Conversion Combination therapy to Enhance Antisense Mediated Exon Skipping for Duchenne Muscular Dystrophy $1,823,545
University of California, Los Angeles Dr. Robert Reiter MD Early Translational IV Clinical Development of an N-cadherin Antibody to Target Cancer Stem Cells $4,075,668
Human BioMolecular Research Institute Dr. John R Cashman Ph.D. Early Translational IV Improving Existing Drugs for Long QT Syndrome type 3 (LQT3) by hiPSC Disease-in-Dish Model $6,361,369
Numerate, Inc. Dr. John H Griffin Early Translational IV Use of human iPSC-derived neurons from Huntington’s Disease patients to develop novel, disease-modifying small molecule structural corrector drug candidates targeting the unique, neurotoxic conformation of mutant huntingtin $520,015
University of California, Los Angeles Dr. Jerome A. Zack Ph.D. Early Translational IV Stem Cell Programming With Chimeric Antigen Receptors to Eradicate HIV Infection $4,925,166
University of California, Los Angeles Dr. Gerald Lipshutz Early Translational IV Gene therapy-corrected autologous hepatocyte-like cells from induced pluripotent stem cells for the treatment of pediatric single enzyme disorders $1,801,629
Cedars-Sinai Medical Center Professor Clive Niels Svendsen Disease Team Therapy Planning I Stem Cells Secreting GDNF for the Treatment of ALS $63,487